Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension

Aprocitentan (ACT-132577) is an orally active, dual endothelin-1 (ET-1) receptor antagonist that prevents the binding of ET-1 to both ETA/ETB receptors. It is an active metabolite of macitentan (obtained by oxidative depropylation), an orphan drug used for the treatment of pulmonary arterial hyperte...

Descripción completa

Detalles Bibliográficos
Autores principales: Angeli, Fabio, Verdecchia, Paolo, Reboldi, Gianpaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555037/
https://www.ncbi.nlm.nih.gov/pubmed/34251649
http://dx.doi.org/10.1007/s40119-021-00233-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555037/
https://www.ncbi.nlm.nih.gov/pubmed/34251649
http://dx.doi.org/10.1007/s40119-021-00233-7

Ejemplares similares